首页 > 市场调查报告书 > 製药

再生医学细胞疗法

南美洲和中美洲T 细胞治疗市场预测至2030 年- 区域分析- 按模式（研究和商业化）、治疗类型[CAR T 细胞疗法和基于T 细胞受体(TCR) 的] 和适应症（血液恶性肿瘤和实体肿瘤）肿瘤）

市场调查报告书

商品编码

1452637

南美洲和中美洲T 细胞治疗市场预测至2030 年- 区域分析- 按模式（研究和商业化）、治疗类型[CAR T 细胞疗法和基于T 细胞受体(TCR) 的] 和适应症（血液恶性肿瘤和实体肿瘤）肿瘤）

South & Central America T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 55 Pages | 订单完成后即时交付

价格

简介目录图表

2022年南美洲和中美洲T细胞治疗市场价值为8,411万美元，预计到2030年将达到2.6559亿美元；预计2022年至2030年CAGR为15.5%。

T 细胞治疗批准数量的增加推动了南美洲和中美洲 T 细胞治疗市场

标靶治疗、更快、更有效的恢復以及减少副作用都是 T 细胞疗法的优点。在全球范围内，细胞疗法由于获得了各种批准而被广泛采用：

2023 年：吉利德旗下 Kite 公司宣布在沙乌地阿拉伯、新加坡和巴西开展业务，作为其商业扩张的一部分。 Kite 已在这三个国家提交了其 CAR T 细胞治疗产品的监管申请。

例如，2022年6月，百时美施贵宝的Breyanzi (lisocabtagene maraleucel) 获得FDA 批准，这是一种CD19 定向嵌合抗原受体(CAR) T 细胞疗法，用于治疗成人大B 细胞淋巴瘤(LBCL ) 患者。

2022年2月，美国食品药物管理局(FDA) 批准Yescarta (axicabtagene ciloleucel) CAR T 细胞疗法用于治疗一线化学免疫疗法难治或一线化学免疫疗法12 个月内復发的大B 细胞淋巴瘤成人患者。 Yescarta 是第一个获得全国综合癌症网络 (NCCN) 1 类推荐的 CAR T 细胞疗法。

2022年2月，FDA核准了ciltacabtagene autoleucel（商品名CARVYKTI）用于治疗经过四线或四线以上治疗（包括蛋白酶体抑制剂、免疫调节剂和抗CD38单株抗体）后復发或难治性多发性骨髓瘤的成年患者。

2022年1月，FDA核准Kimmtrak（tebentafusp-tebn）用于治疗HLA-A*02:01阳性的不可切除或转移性葡萄膜黑色素瘤患者。

2021年3月，Abecma（idecabtagene vicleucel）被FDA核准用于治疗復发或难治性多发性骨髓瘤。该疗法是一种针对 B 细胞成熟抗原 (BCMA) 的转基因自体 T 细胞免疫疗法，适用于治疗患有难治性多发性骨髓瘤的成年患者。

因此，越来越多的 T 细胞疗法获批正在推动市场成长。

南美洲和中美洲 T 细胞治疗市场概述

南美洲和中美洲 T 细胞治疗市场仅限于巴西，因为该产品仅在该国获得批准和商业化。根据《巴西癌症学杂誌》报道，预计 2023 年至 2025 年期间将新增约 704,000 例癌症病例。据估计，巴西每年诊断出超过 12,000 例非何杰金氏淋巴瘤 (NHL) 病例。巴西卫生监管机构(ANVISA) 已在巴西批准了两种CAR T 细胞疗法：tisagenlecleucel（诺华公司），用于治疗患有RR B 细胞急性淋巴细胞白血病(ALL) 的儿科患者和年轻人以及患有復发/难治性(RR) 的成人患者瀰漫性大 B 细胞淋巴瘤和 ciltacabtagene autoleucel (cilta-cel) 用于治疗復发/难治性多发性骨髓瘤 (RRMM) 患者。此外，2022年8月，吉利德旗下公司Kite透过在巴西、新加坡和沙乌地阿拉伯开展业务来扩大业务。 Kite 已提交其 CAR T 细胞治疗产品的监管申请。癌症和淋巴瘤病例的增加以及 T 细胞疗法的应用和临床试验数量的增加预计将在未来几年推动需求。

南美洲和中美洲 T 细胞治疗市场收入及 2030 年预测（百万美元）

南美洲和中美洲 T 细胞治疗市场细分

南美洲和中美洲 T 细胞治疗市场分为模式、治疗类型、适应症和国家。

根据模式，南美洲和中美洲 T 细胞治疗市场分为研究和商业化市场。 2022年，商业化细分市场将占据更大的市场份额。

根据治疗类型，南美洲和中美洲T细胞治疗市场分为CAR T细胞疗法和T细胞受体（TCR）疗法。 2022年，CAR T细胞疗法领域将占据更大的市场份额。

根据适应症，南美洲和中美洲 T 细胞治疗市场分为血液恶性肿瘤和实体肿瘤。 2022 年，血液恶性肿瘤细分市场占据最大市场。

从国家来看，南美洲和中美洲 T 细胞治疗市场仅限于巴西。 2022 年，巴西在南美洲和中美洲 T 细胞治疗市场份额中占据主导地位。

百时美施贵宝公司、吉利德科学公司、杨森全球服务有限责任公司和诺华公司是南美洲和中美洲 T 细胞治疗市场的一些领导公司。

In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 12 months of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.

In February 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for treating adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma patients who are HLA-A*02:01 positive.

In March 2021, Abecma (idecabtagene vicleucel) was approved by the FDA for treating relapsed or refractory multiple myeloma. The treatment is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy indicated for treating adult patients with refractory multiple myeloma.

Therefore, the increasing number of approvals for T-cell therapies is fueling the market growth.

South & Central America T Cell Therapy Market Overview

The South & Central America T-cell therapy market is limited to Brazil as the products are only approved and commercially available in the country. According to the Brazilian Journal of Cancerology, it is estimated that ~704,000 new cases of cancer are expected during 2023-2025. More than 12,000 non-Hodgkin lymphoma (NHL) cases in Brazil are estimated to be diagnosed yearly. The Brazilian Health Regulatory Agency (ANVISA) has approved two CAR T-cell therapies in Brazil: tisagenlecleucel (by Novartis) for pediatric patients and young adults with RR B-cell acute lymphoblastic leukemia (ALL) and adults with relapsed/refractory (RR) diffuse large B-cell lymphoma, and ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM). Moreover, in August 2022, Kite, a Gilead Company, expanded its business by launching operations in Brazil, Singapore, and Saudi Arabia. Kite has submitted regulatory applications for its CAR T-cell therapy products. The rising cases of cancer and lymphoma, and the increasing number of applications and clinical trials for T-cell therapies are expected to boost the demand in the coming years.

South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

South & Central America T Cell Therapy Market Segmentation

The South & Central America T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the South & Central America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the South & Central America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the South & Central America T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the South & Central America T cell therapy market is limited to Brazil. Brazil dominated the South & Central America T cell therapy market share in 2022.

Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, and Novartis AG are some of the leading companies operating in the South & Central America T cell therapy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 South & Central America T Cell Therapy Market, by Country (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. South & Central America T Cell Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Growing Burden of Cancer Worldwide
- 4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
- 4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
- 4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
- 4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:

5. T Cell Therapy Market - South & Central America Market Analysis

5.1 South & Central America T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

6. South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

6.1 Overview
6.2 South & Central America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
- 6.3.1 Overview
- 6.3.2 Research: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
- 6.4.1 Overview
- 6.4.2 Commercialized: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

7. South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

7.1 Overview
7.2 South & Central America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
- 7.3.1 Overview
- 7.3.2 CAR T-cell Therapy: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
- 7.4.1 Overview
- 7.4.2 T-cell Receptor (TCR)-based: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

8.1 Overview
8.2 South & Central America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
- 8.3.1 Overview
- 8.3.2 Hematologic Malignancies: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.3 South & Central America T Cell Therapy Market , by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
- 8.4.1 Overview
- 8.4.2 Solid Tumor: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. South & Central America T Cell Therapy Market - Country Analysis

9.1 Overview
- 9.1.1 South & Central America T Cell Therapy Market by Country
  - 9.1.1.1 Brazil
    - 9.1.1.1.1 Brazil: South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.1.1.2 Brazil: South & Central America T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 9.1.1.1.3 Brazil: South & Central America T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 9.1.1.1.4 Brazil: South & Central America T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 9.1.1.1.4.1 Brazil: South & Central America T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)

10. T Cell Therapy Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Janssen Global Services LLC
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Gilead Sciences Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Bristol-Myers Squibb Co
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Novartis AG
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. South & Central America T Cell Therapy Market Segmentation 8
Table 2. South & Central America T Cell Therapy Market , by Hematological Malignancies - Revenue and Forecast to 2030 (US$ Million)
Table 3. Brazil: South & Central America T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 4. Brazil: South & Central America T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 5. Brazil: South & Central America T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 6. Brazil: South & Central America T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 7. Recent Organic Growth Strategies in South & Central America T Cell Therapy Market
Table 8. Recent Inorganic Growth Strategies in the South & Central America T Cell Therapy Market
Table 9. Glossary of Terms, South & Central America T Cell Therapy Market

List Of Figures

Figure 1. South & Central America T Cell Therapy Market Segmentation, By Country 9
Figure 2. South & Central America T Cell Therapy Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. South & Central America T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
Figure 5. South & Central America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 6. Research: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Commercialized: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. South & Central America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 9. CAR T-cell Therapy: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. T-cell Receptor (TCR)-based: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. South & Central America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 12. Hematologic Malignancies: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Solid Tumor: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. South & Central America T Cell Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
Figure 15. South & Central America T Cell Therapy Market , By Key Countries, 2022 and 2030 (%)
Figure 16. Brazil: South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Growth Strategies in T Cell Therapy Market